MEDP
Medpace Holdings, Inc.
Diagnostics & Research · Healthcare · United States
677.56
close · 2026-10-29
value
22
cheaper than peers22
quality
95
stronger fundamentals95
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 27.84× | 44 |
| forward P/E | 34.13× | 43 |
| price to sales | 6.65× | 34 |
| price to book | 32.39× | 5 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 162.2% | 98 |
| operating margin | 20.8% | 85 |
| debt to equity | 33.2% | 67 |
| revenue growth | 17.2% | 63 |
4 of 4 measures available
Facts
| market cap | $19B |
| free cash flow | $510.4M |
| employees | 6,500 |
| first trade | 2016-08-11 |
| next earnings | 2026-10-21 |
| fundamentals updated | 2026-10-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 15.28 | 12.63 | 8.88 | 7.28 |
| free cash flow | $681.9M | $572.3M | $396.7M | $351.2M |
| net income | $451.1M | $404.4M | $282.8M | $245.4M |
| revenue | $2.53B | $2.11B | $1.89B | $1.46B |
| unusual items | -$7.7M | -$496,000 | -$1.9M | $3.9M |